Trial Profile
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2018
Price :
$35
*
At a glance
- Drugs Brimapitide (Primary)
- Indications Sensorineural hearing loss
- Focus Therapeutic Use
- Sponsors Auris Medical
- 04 Jan 2018 Pooled results from this and a phase III HEALOS trial, published in an Auris Medical media release.
- 18 Sep 2014 New trial record